Acute Ischemic Stroke Overview
Acute Ischemic Stroke (AIS) occurs when blood flow through a brain artery is blocked by a clot- amass of thickened blood. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, more common of the two, occurs when a clot forms within an artery in the brain
“Acute Ischemic Stroke Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Ischemic Stroke Market.
The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Acute Ischemic Stroke Pipeline Report:
- Companies across the globe are diligently working toward developing novel Acute Ischemic Stroke treatment therapies with a considerable amount of success over the years. Acute Ischemic Stroke Key players such as – Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, AbbVie, and others, are developing therapies for the Acute Ischemic Stroke treatment
- Acute Ischemic Stroke Emerging therapies such as – MultiStem, BMS986177, LT-3001, Elezanumab, and others are expected to have a significant impact on the Acute Ischemic Stroke market in the coming years.
Route of Administration
Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Acute Ischemic Stroke Pipeline Therapeutics Assessment
- Acute Ischemic Stroke Assessment by Product Type
- Acute Ischemic Stroke By Stage and Product Type
- Acute Ischemic Stroke Assessment by Route of Administration
- Acute Ischemic Stroke By Stage and Route of Administration
- Acute Ischemic Stroke Assessment by Molecule Type
- Acute Ischemic Stroke by Stage and Molecule Type
DelveInsight’s Acute Ischemic Stroke Report covers around 35+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of the key companies in the Acute Ischemic Stroke Therapeutics Market include:
Key companies developing therapies for the Acute Ischemic Stroke treatment are – Roche, Boehringer Ingelheim, Bayer, Sanofi, Pfizer, and others
Emerging Acute Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:
- MultiStem: Athersys/Healios K.K.
- BMS986177: Bristol-Myers Squibb
- LT-3001: Lumosa Therapeutics
- Elezanumab: AbbVie
Get a Free Sample PDF Report to know more about Acute Ischemic Stroke Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-pipeline-insight
Acute Ischemic Stroke Pipeline Analysis:
The Acute Ischemic Stroke pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Acute Ischemic Stroke with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Ischemic Stroke Treatment.
- Acute Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Acute Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Ischemic Stroke market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Acute Ischemic Stroke product details are provided in the report. Download the Acute Ischemic Stroke pipeline report to learn more about the emerging Acute Ischemic Stroke therapies
Scope of Acute Ischemic Stroke Pipeline Drug Insight
- Coverage: Global
- Key Acute Ischemic Stroke Companies: Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, AbbVie, and others
- Key Acute Ischemic Stroke Therapies: MultiStem, BMS986177, LT-3001, Elezanumab, and others
- Acute Ischemic Stroke Therapeutic Assessment: Acute Ischemic Stroke current marketed and Acute Ischemic Stroke emerging therapies
- Acute Ischemic Stroke Market Dynamics: Acute Ischemic Stroke market drivers and Acute Ischemic Stroke market barriers
Request for Sample PDF Report for Acute Ischemic Stroke Pipeline Assessment and clinical trials
Table of Contents
1 |
Acute Ischemic Stroke Report Introduction |
2 |
Acute Ischemic Stroke Executive Summary |
3 |
Acute Ischemic Stroke Overview |
4 |
Acute Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment |
5 |
Acute Ischemic Stroke Pipeline Therapeutics |
6 |
Acute Ischemic Stroke Late Stage Products (Phase II/III) |
7 |
Acute Ischemic Stroke Mid Stage Products (Phase II) |
8 |
Acute Ischemic Stroke Early Stage Products (Phase I) |
9 |
Acute Ischemic Stroke Preclinical Stage Products |
10 |
Acute Ischemic Stroke Therapeutics Assessment |
11 |
Acute Ischemic Stroke Inactive Products |
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
13 |
Acute Ischemic Stroke Key Companies |
14 |
Acute Ischemic Stroke Key Products |
15 |
Acute Ischemic Stroke Unmet Needs |
16 |
Acute Ischemic Stroke Market Drivers and Barriers |
17 |
Acute Ischemic Stroke Future Perspectives and Conclusion |
18 |
Acute Ischemic Stroke Analyst Views |
19 |
Appendix |
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Acute Ischemic Stroke drugs and therapies
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com